Xencor
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
465 N Halstead St Ste 200, Pasadena, Cal...Phone Number
(626) 305-5900Website
www.xencor.comRevenue
$97.4 MillionStock Symbol
XNCRIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
1
1
1
About Xencor
Xencor Inc. is a clinical-stage biopharmaceutical company. It focuses on the development of engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company was founded in 1997 and is based in Pasadena, California.Explore more
Xencor Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Xencor your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Xencor has new funding data
Earning: See what the market has to say on Xencor recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Xencor
Click to see if Xencor had a recent Job posting/layoffs
Check out if Xencor is spiking on competitors!
Product Launch: Get notified when Xencor launches new products
Check if Xencor has recently received funding, and reach out quickly before it becomes old news!
Xencor, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Xencor as Masked Content
Find more new buyers
Compare Similar Companies to Xencor
Compare insights from companies similar to Xencor, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Xencor
$97.4M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
$114.2M
51-200
Public
$462.1M
1994
JB
Jennifer BuellPresident and CEO of MiNK Therapeutics, Chairman, Executive Council At Agenus
Company Profile Activity
Activity Insights
Xencor is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Xencor is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Xencor.
Xencor financials insights
Gather financial insights about Xencor, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
1999
Series B
$12.3M
2000
Series C
$50M
2005
Series D
$10M
2007
Series E
$60M
2010
Debt
$7.5M
2013
Stock Offering
$72.4M
2021
Share Placement
$25M
Xencor Tech Stack
A closer look at the technologies used by Xencor
See more technologies
Most Recent Scoops
Person-Based
Pharmaceuticals, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Spending/Investment
Open Position
Xencor News & Media
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 May 5, 2026 8:00 AM EDTCompany ParticipantsCharles Liles -...Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (XNCR) Barclays 28th Annual Global Healthcare Conference March 11, 2026 11:30 AM EDTCompany ParticipantsBassil Dahiyat - Co-Founder, CEO,...Xencor (XNCR): BofA Bullish on US Biopharmaceuticals Coverage
Xencor Inc. (NASDAQ:XNCR) is one of the best high short interest stocks with biggest upside potential. On January 6, Bank of America raised its price target for Xencor to $20 from $17 while maintaining a Neutral rating. This sentiment was announced by the firm as part of its broader update to its US Biopharmaceuticals coverage. […]RBC Cuts Xencor (XNCR) Price Target but Keeps Outperform Rating
Xencor, Inc. (NASDAQ:XNCR) is one of the Top 10 Stocks Under $10 That Could Triple. On August 21, RBC Capital reduced its price target for Xencor, Inc. (NASDAQ:XNCR) from $32 to $15 and maintained an Outperform rating. Despite lowering the price target, the firm believes that the current share price does not reflect the full […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Xencor
Sign Up For FreeTo access detailed company insights
Xencor Inc. is a clinical-stage biopharmaceutical company. It focuses on the development of engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company was founded in 1997 and is based in Pasadena, California.... Read More
